2 min readNew Path to Cancer Therapy: Developing Simultaneous Multiplexed Gene Editing Technology

Seoul, Korea — Dr. Mihue Jang and her group at the Center for Theragnosis of the Korea Institute of Science and Technology (KIST, President Byung-gwon Lee) announced that they have developed a new gene editing system that could be used for anticancer immunotherapy through the simultaneous suppression of proteins that interfere with the immune system expressed on the surface of lymphoma cells* and activation of cytotoxic T lymphocyte**, based on the results of joint research conducted with Prof. Seokmann Hong and his group at Sejong University (President, Deg-hyo Bae).

*Lymphoma cell: a broad term for cancers of the blood system, referring to malignant tumours in the blood, hematopoietic organs, lymph nodes, and/or lymphoid organs

**Cytotoxic T lymphocyte (CTL): a type of T lymphocyte that directly kills tumour cells or cells infected with viruses by secreting cytotoxic substances

Gene editing technology is a technology that eliminates the underlying causes of and treats diseases by removing specific genes or editing genes to restore their normal function. In particular, CRISPR gene editing technology*** is now commonly used for immunotherapy by correcting the genes of immune cells to induce them to attack cancer cells selectively.

***CRISPR gene editing technology: Based on the proteins involved in bacterial immune reactions, this technology selectively corrects genes through the simultaneous action of Cas9 proteins with gene-cutting function and single guide RNA (sgRNA), which enables genome sequence selectivity.

Dr. Mihue Jang of KIST improved the CRISPR gene editing system to enable the penetration of the cell membrane without external carriers. However, there are various kinds of genes that regulate immune activity, and technology for inducing safe and convenient immunotherapy is not yet sufficiently developed. The collaborative research team of Dr. Jang’s group at KIST and Prof. Hong’ group at Sejong University developed a technology that is applicable to immunotherapy by further improving the CRISPR gene editing system to allow for the transfer of genes to lymphoma cells without external carriers as well as the correction of several genes at the same time.

Existing gene editing technology has been used to transfer genes into lymphoma cells, such as T lymphocytes, among immune cells, mainly using the viral transduction or electroporation methods. The viral transduction method often induces undesired immune responses and has a high chance of inserting genes into the wrong genome sequences. Also, the electric shock method requires separate and expensive equipment, has great difficulty correcting large numbers of cells at one time, and shows low cell viability.

This technology jointly developed by research teams of KIST and Sejong University simultaneously targets PD-L1 and PD-L2, among the inhibitory immune checkpoints**** known for suppressing the immune system. The treatment efficacy was confirmed, showing that targeting these immune checkpoints does not interfere with the immune system and that the cytotoxic T lymphocytes directly attack cancer cells to increase the anticancer immune response.

****Inhibitory immune checkpoints: a kind of mechanism that regulates the antigen recognition of T cell receptors (TCR) in the immune response process and interferes with the destruction of cancer cells

Dr. Mihue Jang of KIST said, “This newly developed gene editing system can be applied to various types of immune cells, and is thus expected to be used in the development of treatments for various diseases, including not only cancers but also autoimmune and inflammatory diseases.”

Article adapted from a National Research Council of Science and Technology news release.

Publication: A carrier-free multiplexed gene editing system applicable for suspension cells. Ju, A et al. Biomaterials (June 25, 2019): Click here to view.

CRISPR, cytotoxic T lymphocyte, Gene editing, Lymphoma cells, Tumour

Leave a Reply

© 2022 Mindzilla. All rights reserved.